These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 1371274

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors.
    Yang G, Song Q, Charles M, Drosopoulos WC, Arnold E, Prasad VR.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr 01; 11(4):326-33. PubMed ID: 8601218
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Catalytic properties of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2.
    Hizi A, Tal R, Shaharabany M, Loya S.
    J Biol Chem; 1991 Apr 05; 266(10):6230-9. PubMed ID: 1706712
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The catalytic properties of the reverse transcriptase of the lentivirus equine infectious anemia virus.
    Rubinek T, Loya S, Shaharabany M, Hughes SH, Clark PK, Hizi A.
    Eur J Biochem; 1994 Feb 01; 219(3):977-83. PubMed ID: 7509281
    [Abstract] [Full Text] [Related]

  • 7. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
    Debyser Z, Vandamme AM, Pauwels R, Baba M, Desmyter J, De Clercq E.
    J Biol Chem; 1992 Jun 15; 267(17):11769-76. PubMed ID: 1376311
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The effects of cysteine mutations on the reverse transcriptases of human immunodeficiency virus types 1 and 2.
    Hizi A, Shaharabany M, Tal R, Hughes SH.
    J Biol Chem; 1992 Jan 15; 267(2):1293-7. PubMed ID: 1370463
    [Abstract] [Full Text] [Related]

  • 11. Mutational analysis of the DNA polymerase and ribonuclease H activities of human immunodeficiency virus type 2 reverse transcriptase expressed in Escherichia coli.
    Hizi A, Tal R, Hughes SH.
    Virology; 1991 Jan 15; 180(1):339-46. PubMed ID: 1701948
    [Abstract] [Full Text] [Related]

  • 12. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
    de Vreese K, Debyser Z, Vandamme AM, Pauwels R, Desmyter J, de Clercq E, Anné J.
    Virology; 1992 Jun 15; 188(2):900-4. PubMed ID: 1374986
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors.
    Hizi A, Tal R, Shaharabany M, Currens MJ, Boyd MR, Hughes SH, McMahon JB.
    Antimicrob Agents Chemother; 1993 May 15; 37(5):1037-42. PubMed ID: 7685994
    [Abstract] [Full Text] [Related]

  • 15. The interaction of illimaquinone, a selective inhibitor of the RNase H activity, with the reverse transcriptases of human immunodeficiency and murine leukemia retroviruses.
    Loya S, Hizi A.
    J Biol Chem; 1993 May 05; 268(13):9323-8. PubMed ID: 7683648
    [Abstract] [Full Text] [Related]

  • 16. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
    Auwerx J, Esnouf R, De Clercq E, Balzarini J.
    Mol Pharmacol; 2004 Jan 05; 65(1):244-51. PubMed ID: 14722257
    [Abstract] [Full Text] [Related]

  • 17. Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor.
    Isaka Y, Sato A, Kawauchi S, Suyama A, Miki S, Hayami M, Fujiwara T.
    Microbiol Immunol; 1998 Jan 05; 42(3):195-202. PubMed ID: 9570285
    [Abstract] [Full Text] [Related]

  • 18. Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds.
    Debyser Z, Pauwels R, Andries K, Desmyter J, Engelborghs Y, Janssen PA, De Clercq E.
    Mol Pharmacol; 1992 Jan 05; 41(1):203-8. PubMed ID: 1370707
    [Abstract] [Full Text] [Related]

  • 19. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
    Debyser Z, De Vreese K, Knops-Gerrits PP, Baekelandt V, Bhikhabhai R, Strandberg B, Pauwels R, Anné J, Desmyter J, De Clercq E.
    Mol Pharmacol; 1993 Apr 05; 43(4):521-6. PubMed ID: 7682649
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.